Soups, shakes and other slimming strategies: GLP-1 agonists vs. NHS type 2 diabetes path to remission programme in the battle against T2DM and weight management
Introduction: Excess body weight increases the risk of cardiometabolic complications, morbidity, and mortality in patients with type 2 diabetes mellitus (T2DM).1 Effective management should prioritise medications that promote weight loss or remain weight-neutral to improve insulin sensitivity and bl...
Saved in:
| Main Authors: | Divanshi Trivedi, Ruth Crowley |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Clinical Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1470211825001770 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of GLP-1 agonists in the treatment of T2DM: A systematic review and network meta-analysis
by: Xiaoyu Ren, et al.
Published: (2025-07-01) -
GLP-1/GLP-1R axis: from metabolism (obesity and T2DM) to immunity
by: Vijay Kumar
Published: (2025-07-01) -
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01) -
Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01) -
Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)